Abbisko Therapeutics - 尊龙Z6官方网站-KNOW MORE

中文
EN

HOME
ABOUT US
- Leadership
- Investors
- SAB
INVESTOR RELATIONS
- Announcements & Notices
- Financial Reports
- Listing Documents
- Investor Calendar
- Investor Presentation
- Corporate Governance
- Stock Information
- IR Contact
SCIENCE
NEWS & PRESS
- pressReleases
- newsMedia
CAREERS
- Career Openings
CONTACT US

Home

About Us

Leadership Investors SAB

Investor Relations

Announcements & Notices Financial Reports Listing Documents Investor Calendar Investor Presentation Corporate Governance Stock Information IR Contact

Science

Research Areas Pipeline Partnership

News&Press

Press Releases Media

Careers

Career Openings

中文
EN

About us

Our Story

Abbisko Therapeutics

We are a R&D-driven, clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative and differentiated small molecule oncology therapies. Since our inception, we have established a robust in-house R&D engine underpinned by our outstanding discovery team and multi-dimensional discovery platform. Leveraging strong discovery capabilities, we have strategically designed and developed a rich pipeline of 10+ programs focused on oncology, including five programs at the clinical stage. We aspire to become a leading biopharmaceutical company that discovers and develops novel, differentiated therapies in cancer and beyond, addressing critical unmet needs for patients in China and globally.

We strategically focus on small molecule precision oncology therapies, small molecule immuno-oncology therapies and their combination therapies, which we believe are the development trends and next-generation solutions to cancer treatment by virtue of their favorable efficacy and safety profiles.

provide deeper efficacy and more overall benefits to patients

Focus

Safety

For patients & society

R&D capabilities

We have established a robust in-house R&D engine underpinned by our outstanding discovery team and multi-dimensional discovery platform.

Our exceptional discovery capability is driven by an experienced team with a prolific track record of drug discovery, as well as a rigorous approach to identify novel and high-quality molecules.

2021

? Completed phase I clinical trial of ABSK091 in Taiwan and commenced phase 1b/II trial in mainland China

? Completed phase Ia clinical trial and ABSK021 in the US and initiated the expansion studies

2021

? Commenced phase 1b trial of ABSK011 in China

? Commenced phase 1b trial of ABSK081 in China

? Obtained clinical approval for conducting phase 1 study of ABSK043 in Australia

? Completed series D financing of US$123 million

2020

? Obtained IND approval from the NMPA to conduct its Phase Ib/II clinical trial of ABSK081 in mainland China

? Completed our series C financing of $42 million led by Temasek

2020

? Commenced the Phase Ia clinical trial of ABSK021 in the United States

? Commenced the Phase Ia clinical trial of ABSK011 in the Taiwan

? Obtained IND approval from the NMPA to conduct its Phase Ib/II clinical trial of ABSK091 in mainland China

2019

? Completed series B financing of $42 million led by Qiming Venture Partners

? Obtained IND approval from NMPA for ABSK011

? Obtained IND approval from FDA for ABSK021

? In-licensed ABSK091 from AstraZeneca with global rights and ABSK081 from X4 Therapeutics with greater China rights

2018

? Selected the second PCC ABSK021, a highly potent and selective CSF-1R inhibitor

? Opened the 4000m2 R&D center in Zhangjiang Hi-Tech Park, Shanghai, China

2017

? Completed series A financing of $28 million led by Lilly Asia Venture

? Selected our first PCC (pre-clinical candidate) ABSK011 for treating HCC and other cancers

2016

? Our company was established in the Zhangjiang Hi-Tech Park, Shanghai, China.

? We started our first two drug discovery programs, ABSK011 and ABSK021.

2016

R&D capabilities

? Our company was established in the Zhangjiang Hi-Tech Park, Shanghai, China.
? We started our first two drug discovery programs, ABSK011 and ABSK021.
2017

R&D capabilities

? Completed series A financing of $28 million led by Lilly Asia Venture
? Selected our first PCC (pre-clinical candidate) ABSK011 for treating HCC and other cancers
2018

R&D capabilities

? Selected the second PCC ABSK021, a highly potent and selective CSF-1R inhibitor
? Opened the 4000m2 R&D center in Zhangjiang Hi-Tech Park, Shanghai, China
2019

R&D capabilities

? Completed series B financing of $42 million led by Qiming Venture Partners
? Obtained IND approval from NMPA for ABSK011
? Obtained IND approval from FDA for ABSK021
? In-licensed ABSK091 from AstraZeneca with global rights and ABSK081 from X4 Therapeutics with greater China rights
2020

R&D capabilities

? Commenced the Phase Ia clinical trial of ABSK021 in the United States
? Commenced the Phase Ia clinical trial of ABSK011 in the Taiwan
? Obtained IND approval from the NMPA to conduct its Phase Ib/II clinical trial of ABSK091 in mainland China
2020

R&D capabilities

? Obtained IND approval from the NMPA to conduct its Phase Ib/II clinical trial of ABSK081 in mainland China
? Completed our series C financing of $42 million led by Temasek
2021

R&D capabilities

? Commenced phase 1b trial of ABSK011 in China
? Commenced phase 1b trial of ABSK081 in China
? Obtained clinical approval for conducting phase 1 study of ABSK043 in Australia
? Completed series D financing of US$123 million
2021

R&D capabilities

? Completed phase I clinical trial of ABSK091 in Taiwan and commenced phase 1b/II trial in mainland China
? Completed phase Ia clinical trial and ABSK021 in the US and initiated the expansion studies

“

Leveraging the experience of our R&D team, we have built a multi-dimensional and innovation-driven discovery platform with comprehensive capabilities in cancer genomics and screening, computational and medicinal chemistry, and translational and biomarker science,which enables us to discover high-quality assets with efficiency.

”